FDA Approves Apalutamide for Metastatic CastrationSensitive Prostate Cancer

FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

22:42 EDT 17 Sep 2019 | OncLive

The FDA has approved apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

More From BioPortfolio on "FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer"